Growth Hormone & IGF Research Peptides

Growth hormone research peptides are studied for their effects on the somatotropic axis — the GHRH/GH/IGF-1 signaling cascade that regulates a wide range of metabolic, anabolic, and developmental processes. The class divides broadly into two pharmacological groups: GHRH analogs (which bind the GHRH receptor on anterior pituitary somatotrophs) and GHRPs/ghrelin-mimetics (which bind the growth hormone secretagogue receptor, GHS-R1a). Research literature characterizes synergistic effects when these two classes are studied in combination — pulse-amplitude amplification rather than simple additive effects.

CJC-1295 (with and without DAC, also known as Modified GRF 1-29) is studied for its effects on GHRH-receptor signaling and downstream pulsatile GH release. Sermorelin is the GHRH(1-29) sequence, the minimum bioactive fragment of full-length GHRH. Tesamorelin (TH9507, GHRH analog with N-terminal modification) is studied for stability-enhanced receptor-binding research. All GHRH analogs are supplied as sterile lyophilized powder for laboratory reconstitution.

GHRP-2 (Pralmorelin) and GHRP-6 are short ghrelin-mimetic hexapeptides studied for GHS-R1a activation. Hexarelin is a related synthetic with high pituitary-receptor potency. Ipamorelin is a selective GHS-R1a agonist studied for its receptor selectivity profile, particularly in research contexts where minimal cortisol or prolactin co-release is desired. Each GHRP is supplied at 5mg or 10mg per vial, lyophilized, with COA on request.

Common research applications include in-vivo animal studies characterizing GH pulse amplitude and IGF-1 expression dose-response; in-vitro receptor pharmacology including selectivity profiling at GHRH-R, GHS-R1a, and related receptor families; comparative pharmacology between GHRH analogs of differing pharmacokinetic profiles; and synergy studies combining GHRH analogs with GHRPs in animal models.

Lyophilized GH research peptides are stable at -20°C for typical 24-month shelf-life windows. After reconstitution with bacteriostatic water, store solutions at 2–8°C and use within the timeframe indicated by lot stability data — typically 14–28 days. Some compounds (notably Ipamorelin) have shorter solution stability and benefit from aliquoting if extended use is required. Always use sterile technique during reconstitution and aspiration to prevent solution contamination.